2021
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, Cai W, Cheng W, Liu SH, Cheng P, Cai Y, Rattray NJW, Johnson CH, Chen L, Cheng YC. YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports 2021, 11: 13482. PMID: 34188068, PMCID: PMC8242098, DOI: 10.1038/s41598-021-91623-3.Peer-Reviewed Original ResearchConceptsM1-like macrophage polarizationMacrophage polarizationIDO activityInterferon gammaInnate immunityTumor microenvironmentTraditional Chinese herbal formulationPD-L1 inductionM1-like macrophagesAdaptive immune responsesM2 macrophage polarizationChinese herbal formulationTumor bearing miceQuality of lifeAnti-tumor activityGastrointestinal symptomsMonocytic MDSCsProlong survivalImmune toleranceAcute inflammationCancer patientsClinical resultsHepatocellular carcinomaImmune responseRadiation therapy
2018
Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
Lam W, Ren Y, Guan F, Jiang Z, Cheng W, Xu CH, Liu SH, Cheng YC. Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906). Frontiers In Pharmacology 2018, 09: 1324. PMID: 30510512, PMCID: PMC6252377, DOI: 10.3389/fphar.2018.01324.Peer-Reviewed Original ResearchHerbal productsAnimal studiesMechanism actionChinese medicine formulationAnti-tumor activityGastrointestinal symptomsPatients' qualityClinical studiesTherapeutic indexLuciferase reporter cell lineChinese formulationRadiation treatmentCancer treatmentQuality control platformReporter cell lineMedicine formulationCell linesFaster recoveryAnticancer agentsPharmacological usageClinical batchesTreatmentAssaysIrinotecanAppropriate biological assays